| Oct 2 |
Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years
|
| Sep 25 |
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
|
| Sep 23 |
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
|
| Sep 19 |
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference
|
| Sep 16 |
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
|
| Sep 13 |
Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
|
| Sep 6 |
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
|
| Sep 5 |
Here's Why Alkermes (ALKS) is a Strong Growth Stock
|
| Sep 4 |
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
|
| Aug 30 |
Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?
|
